191 related articles for article (PubMed ID: 31856887)
1. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.
Bradley JM; Anand R; O'Neill B; Ferguson K; Clarke M; Carroll M; Chalmers J; De Soyza A; Duckers J; Hill AT; Loebinger MR; Copeland F; Gardner E; Campbell C; Agus A; McGuire A; Boyle R; McKinney F; Dickson N; McAuley DF; Elborn S;
Trials; 2019 Dec; 20(1):747. PubMed ID: 31856887
[TBL] [Abstract][Full Text] [Related]
2. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
[TBL] [Abstract][Full Text] [Related]
3. Interventions for bronchiectasis: an overview of Cochrane systematic reviews.
Welsh EJ; Evans DJ; Fowler SJ; Spencer S
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010337. PubMed ID: 26171905
[TBL] [Abstract][Full Text] [Related]
4. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM; Smith S
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001506. PubMed ID: 37319354
[TBL] [Abstract][Full Text] [Related]
5. Timing of hypertonic saline inhalation for cystic fibrosis.
Elkins M; Dentice R
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD008816. PubMed ID: 32107770
[TBL] [Abstract][Full Text] [Related]
6. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis.
Kellett F; Robert NM
Respir Med; 2011 Dec; 105(12):1831-5. PubMed ID: 22018993
[TBL] [Abstract][Full Text] [Related]
7. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.
Nicolson CH; Stirling RG; Borg BM; Button BM; Wilson JW; Holland AE
Respir Med; 2012 May; 106(5):661-7. PubMed ID: 22349069
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
9. Inhaled hyperosmolar agents for bronchiectasis.
Hart A; Sugumar K; Milan SJ; Fowler SJ; Crossingham I
Cochrane Database Syst Rev; 2014 May; 2014(5):CD002996. PubMed ID: 24817558
[TBL] [Abstract][Full Text] [Related]
10. Dual antibiotics for bronchiectasis.
Felix LM; Grundy S; Milan SJ; Armstrong R; Harrison H; Lynes D; Spencer S
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012514. PubMed ID: 29889304
[TBL] [Abstract][Full Text] [Related]
11. Nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalised with acute bronchiolitis: protocol for a randomised, double-blind, multicentre trial.
Szupieńko S; Buczek A; Szymański H
BMJ Open; 2023 Nov; 13(11):e080182. PubMed ID: 38011984
[TBL] [Abstract][Full Text] [Related]
12. Timing of hypertonic saline inhalation for cystic fibrosis.
Elkins M; Dentice R
Cochrane Database Syst Rev; 2012 Feb; (2):CD008816. PubMed ID: 22336853
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis.
Kellett F; Redfern J; Niven RM
Respir Med; 2005 Jan; 99(1):27-31. PubMed ID: 15672845
[TBL] [Abstract][Full Text] [Related]
14. Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial.
San Miguel-Pagola M; Reychler G; Cebrià I Iranzo MA; Gómez-Romero M; Díaz-Gutiérrez F; Herrero-Cortina B
Physiotherapy; 2020 Jun; 107():243-251. PubMed ID: 32026826
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Nebulised hypertonic saline for cystic fibrosis.
Wark PA; McDonald V; Jones AP
Cochrane Database Syst Rev; 2005 Jul; (3):CD001506. PubMed ID: 16034863
[TBL] [Abstract][Full Text] [Related]
17. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.
Herrero-Cortina B; Alcaraz V; Vilaró J; Torres A; Polverino E
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):281-289. PubMed ID: 29878856
[TBL] [Abstract][Full Text] [Related]
18. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
19. Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Claudius C; Perner A; Møller MH
Syst Rev; 2015 Nov; 4():153. PubMed ID: 26547839
[TBL] [Abstract][Full Text] [Related]
20. Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.
Chang AB; Yerkovich ST; Baines KJ; Burr L; Champion A; Chatfield MD; Eg KP; Goyal V; Marsh RL; McCallum GB; McElrea M; McPhail S; Morgan LC; Morris PS; Nathan AM; O'Farrell H; Sanchez MO; Parsons M; Schultz A; Torzillo PJ; West NP; Versteegh L; Marchant JM; Grimwood K
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38719503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
